Analyst Price Target is $47.57
▲ +109.11% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Repare Therapeutics in the last 3 months. The average price target is $47.57, with a high forecast of $54.00 and a low forecast of $38.00. The average price target represents a 109.11% upside from the last price of $22.75.
Current Consensus is
The current consensus among 7 polled investment analysts is to buy stock in Repare Therapeutics.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in MontrÃ©al, Canada.